Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 8071 AL 8085

Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity

Moscoso A, Heeman F, Raghavan S, Costoya-Sánchez A, van Essen M, Mainta I, Camacho V, Rodríguez-Fonseca O, Silva-Rodríguez J, Perissinotti A, Gu Y, Yun J, Peretti D, Ribaldi F, Coomans EM, Brum WS, Grothe MJ, Aguiar P, Bischof GN, Drzezga A, Seo SW, Villeneuve S, Malpetti M, O'Brien JT, Rowe JB, van de Giessen EM, Ossenkoppele R, Jagust WJ, Smith R, Hansson O, Frisoni GB, Garibotto V, Soleimani-Meigooni DN, Carrillo M, Dickerson BC, La Joie R, Rabinovici GD, Apostolova LG, LaMontagne PJ, Pontecorvo MJ, Johnson KA, Sperling RA, Weiner MW, Petersen RC, Jack CR Jr, Vemuri P, Schöll M; PREVENT-AD Research Group, the Harvard Aging Brain Study, the LEADS Consortium, and the Alzheimer’s Disease Neuroimaging Initiative.

JAMA. 2025 Jul 15;334(3):229-242. doi: 10.1001/jama.2025.7817.

Deferiprone in Alzheimer Disease: A Randomized Clinical Trial

Ayton S, Barton D, Brew B, Brodtmann A, Clarnette R, Desmond P, Devos D, Ellis KA, Fazlollahi A, Fradette C, Goh AMY, Kalinowski P, Kyndt C, Lai R, Lim YY, Maruff P, O'Brien TJ, Rowe C, Salvado O, Schofield PW, Spino M, Tricta F, Wagen A, Williams R, Woodward M, Bush AI.

JAMA Neurol. 2025 Jan 1;82(1):11-18. doi: 10.1001/jamaneurol.2024.3733.

High circulating adropin levels predict long-term blood pressure variability in old adults: evidence from the Multidomain Alzheimer Prevention Trial

Aggarwal G, Salas J, Vellas B, Nguyen AD, Butler AA; MAPT/IHU HealthAge Open Science Group.

Am J Physiol Heart Circ Physiol. 2025 Dec 1;329(6):H1684-H1692. doi: 10.1152/ajpheart.00763.2025. Epub 2025 Nov 18.

Validation status of cognitive digital assessments by the FDA BEST framework and context of use in preclinical AD studies: A systematic review

Porta-Mas C, Grau-Rivera O, Gispert JD, Blasco GS, Sánchez-Benavides G.

Alzheimers Dement. 2025 Dec;21(12):e70753. doi: 10.1002/alz.70753.

Amyloid Clearance and Transient CSF Aβ40 Reduction in a Case of ARIA-E/H Following Lecanemab Treatment

Naeshiro Y, Kitani-Morii F, Kasai T, Tanaka E, Kobayashi F, Ohara T.

Intern Med. 2026 Apr 1;65(7):1056-1060. doi: 10.2169/internalmedicine.6070-25. Epub 2025 Aug 21.

Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?

Ricaurte-Fajardo A, Ivanidze J, Zhang D, Mahmud M, Yasen W, Ravdin L, Pahlajani S, Leon M, Nordvig AS, Chiang GC.

AJNR Am J Neuroradiol. 2025 Jul 1;46(7):1439-1445. doi: 10.3174/ajnr.A8654.

The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence

Aisen P, Bateman RJ, Crowther D, Cummings J, Dwyer J, Iwatsubo T, Kosco-Vilbois M, McDade E, Mohs R, Scheltens P, Sperling R, Selkoe D.

Alzheimers Dement. 2025 Jan;21(1):e14342. doi: 10.1002/alz.14342. Epub 2024 Nov 13.

Identifying a combination of biomarkers to predict treatment response to nabilone for agitation in Alzheimer's disease - an exploratory post hoc analysis

Wang HJ, Ruthirakuhan M, Andreazza AC, Beroncal EL, Black SE, Gallagher D, Herrmann N, Kiss A, Verhoeff NPLG, Lanctôt KL.

Neurodegener Dis Manag. 2026 Apr-Jun;16(3):263-272. doi: 10.1080/17582024.2025.2587549. Epub 2025 Nov 11.

Mass spectrometry-based methods for biofluid biomarkers for progressive diseases: amyloid peptides and dystrophins

Niwa M, Noda K, Kobayashi Y, Kageyama I, Kodama K.

Bioanalysis. 2025 May;17(10):671-680. doi: 10.1080/17576180.2025.2515011. Epub 2025 Jun 4.

Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease

Cline EN, Antwi-Berko D, Sundell K, Johnson E, Hyland M, Zhang H, Vanderstichele H, Kaplow J, Dean RA, Stoops E, Vanmechelen E, Koel-Simmelink MJA, Teunissen CE, Sethuraman G, Feaster T, Siemers E, Jerecic J.

J Prev Alzheimers Dis. 2025 Apr;12(4):100082. doi: 10.1016/j.tjpad.2025.100082. Epub 2025 Feb 17.

Potential beneficial effects of PD-1/PD-L1 blockade in Alzheimer's disease: a systematic review and meta-analysis of preclinical and clinical studies

Yoon J, Ha H, Lee HW, Kim S, Yu YM, Chun H.

Mol Psychiatry. 2026 Feb;31(2):1156-1166. doi: 10.1038/s41380-025-03413-2. Epub 2025 Dec 15.

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials

Abushakra S, Doraiswamy PM, Hey JA, Tosun D, Barkhof F, Barakos J, Petrella J, Kesslak JP, Power A, Sabbagh M, Porsteinsson A, Cohen S, Gauthier S, Ritchie C, Watson D, McSweeney E, Boada M, Liang E, Bracoud L, McLaine R, Flint S, Schaefer JF, Yu J, Bray M, Hendrix S, Dickson S, Durrant A, Albayrak A, Tolar M.

CNS Drugs. 2026 Feb;40(2):199-214. doi: 10.1007/s40263-025-01251-y. Epub 2025 Dec 1.

Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid-beta drugs in Alzheimer's disease: a Bayesian meta-analysis

Ren S, Singh J, Gsteiger S, Cogley C, Reed B, Abrams KR, Dawoud D, Owen RK, Tappenden P, Quinn TJ, Bujkiewicz S.

J Comp Eff Res. 2026 Jan;15(1):e250095. doi: 10.57264/cer-2025-0095. Epub 2025 Dec 2.

PDE5 Inhibitors as Modulators of Alzheimer's-Associated Inflammation and Oxidative Stress: A Meta-Analytical Assessment of Preclinical Studies

Uppuluri CT, Prasad YSKV, Asadi K, Kumari TP, Pelluri R, Chakravarthi G, Nalluri BN, Gurram PC.

Mol Neurobiol. 2025 Dec 23;63(1):322. doi: 10.1007/s12035-025-05635-5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias